CYP19A1 and breast carcinoma: The most common pharmacological therapeutic strategies for patients with ER+ breast cancer are endocrine therapies including selective estrogen receptors α (ERα) modulators, such as tamoxifen, selective ERα down-regulators and aromatase inhibitors (AIs)2.